Welcome to our dedicated page for Estrella Immunopharma SEC filings (Ticker: ESLA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Estrella Immunopharma, Inc. filings document registration statement disclosures, material event reports, capital-structure matters, and governance updates for a clinical-stage biopharmaceutical issuer. The record includes S-1/A registration materials and Form 8-K reports covering securities purchase agreements, registered direct offering and private placement disclosures, common stock, pre-funded warrants, and Nasdaq-listed ESLAW warrants.
Other filings address clinical disclosures for the STARLIGHT-1 study of EB103, Nasdaq continued-listing compliance matters, board appointments, shareholder meeting obligations, emerging growth company status, operating and financial results, risk factors, and material agreements tied to Estrella's ARTEMIS T-cell therapy programs.
Estrella Immunopharma (ESLA) reported that it completed the second dose cohort in the Phase I portion of its STARLIGHT-1 Phase I/II clinical trial of EB103. The company announced the milestone via a press release dated November 3, 2025, which is furnished as Exhibit 99.1 to this report.
Estrella Immunopharma director Jia Dengyao filed an initial Form 3 reporting no securities beneficially owned in the company. The form lists Dengyao's relationship to the issuer as a director and provides a business address. Table entries indicate there are no non-derivative or derivative holdings to report, and the reporting person signed the filing certifying the accuracy of the statement.
Estrella Immunopharma, Inc. reported that Nasdaq has confirmed the company is back in full compliance with key continued listing rules. The first Nasdaq letter states Estrella has regained compliance with the minimum bid price requirement, after the company’s common stock maintained a closing bid of at least $1.00 per share for 10 consecutive business days from September 9, 2025 through September 22, 2025. Nasdaq now considers this bid-price matter closed.
The second Nasdaq letter confirms Estrella has also regained compliance with the minimum market value of listed securities requirement, as its market value of listed securities was at least $35,000,000 for 17 consecutive business days from August 28, 2025 through September 22, 2025. With both issues resolved, the company’s Nasdaq listing is no longer under these compliance deficiencies.
Estrella Immunopharma, Inc. reported a change in its leadership structure. On September 22, 2025, the Board of Directors appointed Jia Dengyao as a member of the Board, effective immediately. As of this report, he has not been appointed, and is not expected to be appointed, to any Board committees.
In connection with his appointment, the Company entered into an indemnification agreement with Mr. Jia on substantially similar terms as those provided to its other non-employee directors. This agreement commits Estrella Immunopharma to cover certain reasonable expenses, such as attorneys’ fees, court costs, and expert fees, that Mr. Jia may incur in actions or proceedings arising from his service as a director or in roles he undertakes at the Company’s request.